O	0	5	First
O	6	15	Incidence
O	16	19	and
O	20	31	Progression
O	32	37	Study
O	38	41	for
B-Disease	42	50	Diabetic
I-Disease	51	62	Retinopathy
O	63	65	in
B-Characteristic	66	74	Portugal
O	74	75	,
O	76	79	the
O	80	90	RETINODIAB
O	91	96	Study
O	96	97	:
O	98	108	Evaluation
O	109	111	of
O	112	115	the
O	116	125	Screening
O	126	133	Program
O	134	137	for
B-Characteristic	138	144	Lisbon
O	145	151	Region
O	151	152	.

O	154	156	To
O	157	165	estimate
O	166	169	the
O	170	171	5
O	171	172	-
O	172	176	year
O	177	186	incidence
O	187	190	and
O	191	202	progression
O	203	205	of
B-Disease	206	214	diabetic
I-Disease	215	226	retinopathy
O	227	228	(
B-Disease	228	230	DR
O	230	231	)
O	232	237	among
O	238	245	persons
O	246	250	with
B-Disease	251	255	type
I-Disease	256	257	2
I-Disease	258	266	diabetes
I-Disease	267	275	mellitus
O	276	277	(
B-Disease	277	279	DM
O	279	280	)
O	280	281	.

O	282	292	Population
O	292	293	-
O	293	298	based
O	298	299	,
O	300	311	prospective
O	311	312	,
O	313	319	cohort
O	320	325	study
O	325	326	.

O	327	330	The
O	331	341	RETINODIAB
O	342	343	(
O	343	348	Study
O	349	354	Group
O	355	358	for
B-Disease	359	367	Diabetic
I-Disease	368	379	Retinopathy
O	380	389	Screening
O	389	390	)
O	391	398	program
O	399	402	was
O	403	414	implemented
O	415	417	in
O	418	421	the
B-Characteristic	422	428	Lisbon
O	429	432	and
B-Characteristic	433	438	Tagus
I-Characteristic	439	445	Valley
O	446	450	area
O	451	458	between
O	459	463	July
O	464	468	2009
O	469	472	and
O	473	481	December
O	482	486	2014
O	486	487	.

O	488	489	A
O	490	495	total
O	496	498	of
O	499	502	109
O	503	506	543
O	507	515	readable
O	516	525	screening
O	526	538	examinations
O	539	543	were
O	544	553	performed
O	554	557	and
O	558	570	corresponded
O	571	573	to
O	574	576	56
O	577	580	903
O	581	589	patients
O	590	593	who
O	594	602	attended
O	603	606	the
O	607	616	screening
O	617	624	program
O	625	627	at
O	628	633	entry
O	633	634	.

O	635	636	A
O	637	642	total
O	643	645	of
O	646	648	30
O	649	652	641
O	653	661	patients
O	662	663	(
O	663	665	53
O	665	666	.
O	666	668	85
O	668	669	%
O	669	670	)
O	671	674	had
O	675	677	at
O	678	683	least
O	684	685	1
O	686	693	further
O	694	703	screening
O	704	709	event
O	710	716	within
O	717	720	the
O	721	726	study
O	727	733	period
O	734	737	and
O	738	742	were
O	743	751	included
O	752	754	in
O	755	758	the
O	759	767	analysis
O	767	768	.

O	769	781	Participants
O	782	791	underwent
O	792	795	two
B-Diagnostic_tool	796	798	45
I-Diagnostic_tool	798	799	Â°
I-Diagnostic_tool	800	815	nonstereoscopic
I-Diagnostic_tool	816	823	retinal
I-Diagnostic_tool	824	831	digital
I-Diagnostic_tool	832	843	photographs
O	844	847	per
B-Anatomy	848	851	eye
O	852	861	according
O	862	864	to
O	865	875	RETINODIAB
O	876	884	protocol
O	884	885	.

O	886	889	All
O	890	896	images
O	897	901	were
O	902	908	graded
O	909	918	according
O	919	921	to
O	922	925	the
B-Classification_system	926	939	International
I-Classification_system	940	948	Clinical
I-Classification_system	949	957	Diabetic
I-Classification_system	958	969	Retinopathy
I-Classification_system	970	975	Scale
O	975	976	.

B-Disease	977	986	Referable
I-Disease	987	995	diabetic
I-Disease	996	1007	retinopathy
O	1008	1009	(
B-Disease	1009	1012	RDR
O	1012	1013	)
O	1014	1017	was
O	1018	1025	defined
O	1026	1029	for
O	1030	1033	all
O	1034	1042	patients
O	1043	1049	graded
O	1050	1052	as
B-Disease	1053	1061	moderate
I-Disease	1062	1078	nonproliferative
I-Disease	1079	1081	DR
O	1082	1083	(
B-Disease	1083	1087	NPDR
O	1087	1088	)
O	1088	1089	,
B-Disease	1090	1096	severe
I-Disease	1097	1101	NPDR
O	1101	1102	,
O	1103	1105	or
B-Disease	1106	1119	proliferative
I-Disease	1120	1122	DR
O	1123	1124	(
B-Disease	1124	1127	PDR
O	1127	1128	)
O	1128	1129	,
O	1130	1134	with
O	1135	1137	or
O	1138	1145	without
B-Disease	1146	1157	maculopathy
O	1158	1160	or
B-Disease	1161	1165	mild
I-Disease	1166	1170	NPDR
O	1171	1175	with
B-Disease	1176	1187	maculopathy
O	1187	1188	.

O	1189	1202	Nonparametric
O	1203	1212	estimates
O	1213	1215	of
O	1216	1219	the
O	1220	1226	annual
O	1227	1230	and
O	1231	1241	cumulative
O	1242	1252	incidences
O	1253	1257	were
O	1258	1266	obtained
O	1267	1269	by
O	1270	1278	Turnbull
O	1278	1279	'
O	1279	1280	s
O	1281	1290	estimator
O	1290	1291	.

O	1292	1304	Associations
O	1305	1312	between
O	1313	1316	the
O	1317	1326	potential
O	1327	1331	risk
O	1332	1339	factors
O	1340	1343	and
O	1344	1347	the
O	1348	1352	time
O	1353	1355	to
O	1356	1361	onset
O	1361	1362	/
O	1362	1373	progression
O	1374	1376	of
B-Disease	1377	1388	retinopathy
O	1389	1393	were
O	1394	1402	assessed
O	1403	1410	through
O	1411	1412	a
O	1413	1423	parametric
O	1424	1432	survival
O	1433	1441	analysis
O	1442	1445	for
O	1446	1454	interval
O	1454	1455	-
O	1455	1463	censored
O	1464	1468	data
O	1468	1469	.

O	1470	1473	The
O	1474	1481	authors
O	1482	1491	estimated
O	1492	1495	the
O	1496	1501	onset
O	1502	1505	and
O	1506	1517	progression
O	1518	1527	incidence
O	1528	1533	rates
O	1534	1536	of
B-Disease	1537	1539	DR
O	1539	1540	.

O	1541	1547	Yearly
O	1548	1557	incidence
O	1558	1560	of
O	1561	1564	any
B-Disease	1565	1567	DR
O	1568	1570	in
O	1571	1579	patients
O	1580	1587	without
B-Disease	1588	1599	retinopathy
O	1600	1602	at
O	1603	1611	baseline
O	1612	1615	was
O	1616	1617	4
O	1617	1618	.
O	1618	1620	60
O	1620	1621	%
O	1622	1623	(
O	1623	1625	95
O	1625	1626	%
O	1627	1637	confidence
O	1638	1646	interval
O	1647	1648	[
O	1648	1650	CI
O	1650	1651	]
O	1651	1652	,
O	1653	1654	3
O	1654	1655	.
O	1655	1657	96
O	1657	1658	-
O	1658	1659	4
O	1659	1660	.
O	1660	1662	76
O	1662	1663	)
O	1664	1666	in
O	1667	1670	the
O	1671	1676	first
O	1677	1681	year
O	1681	1682	,
O	1683	1693	decreasing
O	1694	1696	to
O	1697	1698	3
O	1698	1699	.
O	1699	1701	87
O	1701	1702	%
O	1703	1704	(
O	1704	1706	95
O	1706	1707	%
O	1708	1710	CI
O	1710	1711	,
O	1712	1713	2
O	1713	1714	.
O	1714	1716	57
O	1716	1717	-
O	1717	1718	5
O	1718	1719	.
O	1719	1721	78
O	1721	1722	)
O	1723	1725	in
O	1726	1729	the
O	1730	1735	fifth
O	1736	1740	year
O	1740	1741	.

O	1742	1744	In
O	1745	1757	participants
O	1758	1762	with
B-Disease	1763	1767	mild
I-Disease	1768	1772	NPDR
O	1773	1775	at
O	1776	1784	baseline
O	1784	1785	,
O	1786	1789	the
O	1790	1801	progression
O	1802	1806	rate
O	1807	1809	to
B-Disease	1810	1813	RDR
O	1814	1816	in
O	1817	1821	year
O	1822	1823	1
O	1824	1827	was
O	1828	1829	1
O	1829	1830	.
O	1830	1832	18
O	1832	1833	%
O	1834	1835	(
O	1835	1837	95
O	1837	1838	%
O	1839	1841	CI
O	1841	1842	,
O	1843	1844	0
O	1844	1845	.
O	1845	1847	96
O	1847	1848	-
O	1848	1849	1
O	1849	1850	.
O	1850	1852	33
O	1852	1853	)
O	1853	1854	.

O	1855	1864	Incidence
O	1865	1867	of
O	1868	1871	any
B-Disease	1872	1874	DR
O	1875	1878	and
B-Disease	1879	1882	RDR
O	1883	1886	and
B-Disease	1887	1889	DR
O	1890	1901	progression
O	1902	1906	rate
O	1907	1911	were
O	1912	1922	associated
O	1923	1927	with
O	1928	1933	known
O	1934	1942	duration
O	1943	1945	of
B-Disease	1946	1954	diabetes
O	1954	1955	,
B-Characteristic	1956	1959	age
I-Characteristic	1960	1962	at
I-Characteristic	1963	1972	diagnosis
O	1972	1973	,
O	1974	1977	and
B-Characteristic	1978	1981	use
I-Characteristic	1982	1984	of
I-Characteristic	1985	1992	insulin
I-Characteristic	1993	2002	treatment
O	2002	2003	.

O	2004	2008	This
O	2009	2021	longitudinal
O	2022	2035	epidemiologic
O	2036	2041	study
O	2042	2050	provides
O	2051	2054	the
O	2055	2060	first
B-Characteristic	2061	2071	Portuguese
O	2072	2081	incidence
B-Disease	2082	2084	DR
O	2085	2089	data
O	2090	2092	in
O	2093	2094	a
O	2095	2100	large
O	2100	2101	-
O	2101	2106	scale
O	2107	2117	population
O	2117	2118	-
O	2118	2123	based
O	2124	2130	cohort
O	2131	2133	of
B-Disease	2134	2138	type
I-Disease	2139	2140	2
I-Disease	2141	2149	diabetes
O	2150	2155	after
O	2156	2157	a
O	2158	2159	5
O	2159	2160	-
O	2160	2164	year
O	2165	2171	follow
O	2171	2172	-
O	2172	2174	up
O	2174	2175	.

B-Characteristic	2176	2184	Duration
I-Characteristic	2185	2187	of
I-Characteristic	2188	2196	diabetes
O	2196	2197	,
B-Characteristic	2198	2201	age
I-Characteristic	2202	2204	at
I-Characteristic	2205	2214	diagnosis
O	2214	2215	,
O	2216	2219	and
B-Characteristic	2220	2227	insulin
I-Characteristic	2228	2237	treatment
O	2238	2242	were
O	2243	2253	associated
O	2254	2258	with
O	2259	2269	increasing
O	2270	2274	risk
O	2275	2277	of
O	2278	2287	incidence
O	2288	2291	and
O	2292	2303	progression
O	2304	2306	of
B-Disease	2307	2309	DR
O	2309	2310	.

O	2311	2312	A
O	2313	2325	personalized
O	2326	2334	schedule
O	2335	2347	distribution
O	2348	2350	of
O	2351	2360	screening
O	2361	2370	intervals
O	2371	2380	according
O	2381	2383	to
O	2384	2387	the
O	2388	2398	individual
O	2399	2406	patient
O	2406	2407	'
O	2407	2408	s
O	2409	2416	profile
O	2417	2423	should
O	2424	2426	be
O	2427	2438	implemented
O	2438	2439	,
O	2440	2444	with
O	2445	2454	resulting
O	2455	2463	benefits
O	2464	2466	in
O	2467	2472	terms
O	2473	2475	of
O	2476	2482	health
O	2483	2488	costs
O	2488	2489	.
